Clinical Trials Results - National Cancer Institute

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

In English \| En español
Search

NCI Home

Cancer Topics


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 597 for your search:

Drug:  aldesleukin
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase IV Study of Low-Dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CWRU-CHIR-1899, CHIR-MA-99-01, CWRU-010002, NCI-G00-1875, NCT00006864

Phase II/III Randomized Study of CD8+ TIL/IL-2 for Metastatic Renal Cell Carcinoma (Summary Last Modified 09/95)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AIS-1061-9320, NCI-V95-0689

Phase II/III Randomized Study of Adjuvant Active Specific Immunotherapy with Autologous Tumor Cells and BCG plus CTX and Low-Dose IL-2 for Stage II/III Renal Cell Adenocarcinoma (Summary Last Modified 09/97)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 75
Sponsor:
Protocol IDs: CNR-9505, EU-95023

Phase II/III Randomized Study of Interleukin-2 and Interferon alfa With Versus Without Fluorouracil for Metastatic Renal Cancer

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 79
Sponsor:
Protocol IDs: FRE-FNCLCC-95009, EU-96026

Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Renal Cell Carcinoma --- A Modified Group C Study (Summary Last Modified 04/88)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: NCI-C87-0001, AECM-8706153, CHNMC-COH-7077, CMGH-8756-S-87A, CWRCC-0987188, DUMC-7988710, FCCC-88982, IDB-MGC-RENAL/RAND, JHOC-87092507, MDA-DM-87059, UAC-345, UCCRC-4998, UPCC-1887, UUMC-2056, VRCC-CHRMS-8831, WSU-C-70387, YALE-HIC-4454, C87-0001

Phase II/III Randomized Trial of High-Dose IL-2 Alone or in Combination with Autologous LAK Cells in Patients with Metastatic or Unresectable Malignant Melanoma --- A Modified Group C Study (Summary Last Modified 04/88)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor:
Protocol IDs: NCI-C87-0002, AECM-8706152, CHNMC-COH-7075, CMGH-8755-S-87A, CWRCC-0787137, DUMC-7958710, IDB-MGC-MEL/RAND, JHOC-87092508, MDA-DM-87056, UAC-343, UCCRC-4985, UKMC-8800110, UPCC-1687, UUMC-2055, VRCC-CHRMS-8832, WSU-C-70487, YALE-HIC-4455, C87-0002

Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Carcinoma of the Colon (Summary Last Modified 01/88)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: UCCRC-4973A, NCI-V87-0310

Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Malignant Melanoma (Summary Last Modified 01/88)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: UCCRC-4973B, NCI-V87-0311

Phase II/III Comparison of Adoptive Immunotherapy with rIL-2 with vs without LAK Cell Infusions in Patients with Advanced Renal Cell Carcinoma (Summary Last Modified 01/88)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor:
Protocol IDs: UCCRC-4973C, NCI-V87-0312

10.

Phase II/III Adoptive Immunotherapy for Metastatic Renal Cell Carcinoma: Systemic IL-2 plus IL-2-Activated/Periodate-Treated Cells (Summary Last Modified 11/90)

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 21 to 70
Sponsor:
Protocol IDs: NYH-1088-350CRC, NCI-V88-0417

11.

Phase II/III Study of Rituximab and Interleukin-2 in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Refractory to Prior Single-Agent Rituximab

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0302013, CHIR-IL2NHL03-A01, NCT00066534

12.

Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: Under 30
Sponsor: NCI
Protocol IDs: COG-AHOD0121, NCT00070187, AHOD0121

13.

Phase III Randomized Study of Posttransplant IL-2 vs No Posttransplant Therapy in Acute Lymphoblastic Leukemia and Malignant non-Hodgkin's Lymphoma Treated with Fractionated TBI/CTX/High-Dose VP-16 Followed by Autologous or Syngeneic Bone Marrow Rescue (Summary Last Modified 02/95)

Phase: Phase III
Type: Treatment
Status: Closed
Age: not over 55
Sponsor:
Protocol IDs: FHCRC-701.1, NCI-V94-0401

14.

Phase III Randomized Study of IL-2 vs Observation Following Autologous Stem Cell Transplantation for Acute Myeloid Leukemia Beyond First Remission

Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 to 60
Sponsor: NCI
Protocol IDs: SWOG-9328, E-S9328

15.

Phase III Randomized, Double-Blind Study of High-Dose Intermittent-Infusion IL-2 with CT-1501R (a Pentoxifylline Metabolite) vs IL-2 with Placebo for Advanced Renal Cell Carcinoma or Metastatic Melanoma (Summary Last Modified 03/95)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: PCI-9430, NCI-V94-0493

16.

Phase III Randomized Study of Interleukin-2 Versus Observation Only After Total Body Irradiation, High-Dose Etoposide, Cyclophosphamide, and Autologous Peripheral Blood Stem Cell Transplantation in Patients With Adult Non-Hodgkin's Lymphoma

Phase: Phase III
Type: Treatment
Status: Completed
Age: 16 to 60
Sponsor: NCI
Protocol IDs: SWOG-9438, NCT00002649

17.

Phase III Randomized Study of Intensively Timed Induction Chemotherapy Followed By Consolidation With the Same Chemotherapy Versus Fludarabine, Cytarabine, and Idarubicin, Followed By Intensification With Either High-Dose Cytarabine and Asparaginase With or Without Subsequent Interleukin-2 or Allogeneic Bone Marrow Transplantation in Children With Previously Untreated Acute Myelogenous Leukemia or Myelodysplastic Syndromes

Phase: Phase III
Type: Treatment
Status: Completed
Age: Under 22
Sponsor: NCI
Protocol IDs: COG-2961, CCG-2961, NCT00002798

18.

Phase III Randomized Adjuvant Study of Interferon Alfa-2b (IFN-A) Alone vs Biochemotherapy Using Cisplatin, Vinblastine, Dacarbazine (DTIC), IFN-A, and Interleukin-2 (IL-2) in Melanoma Patients with Regional Lymph Node Metastases

Phase: Phase III
Type: Treatment
Status: Closed
Age: 10 to 70
Sponsor: NCI
Protocol IDs: MDA-ID-95196, MDA-DM-95196, NCI-G96-1089, NCT00002882

19.

Phase III Study of High Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Filgrastim (G-CSF), Melphalan, Radiotherapy, Autologous Peripheral Blood Stem Cell Transplantation, and Interleukin-2 in Patients with Previously Untreated De Novo or Secondary Acute Myeloid Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 25
Sponsor: NCI
Protocol IDs: RPCI-DS-96-48, NCI-G97-1152, NCT00002945

20.

Phase III Study of Cisplatin, Vinblastine, and Dacarbazine With or Without Interleukin-2 and Interferon alfa-2b in Patients With Metastatic Malignant Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-E3695, CLB-509802, SWOG-E3695, NCT00003027, E3695

21.

Phase III Randomized Study of Adjuvant High-Dose Interleukin-2 in Patients With Stage III or IV High-Risk Renal Cell Carcinoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: Other
Protocol IDs: CWG-LU-8520, NCI-V97-1351, NCT00003126

22.

Phase III Randomized Study of Interleukin-2 With or Without Histamine Dihydrochloride in Patients with Stage IV Malignant Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: MAXIM-US-M01, NCI-V98-1382

23.

Phase III Randomized Study of Chemotherapy Followed By Interleukin-2 Versus No Further Therapy in Patients With Acute Myeloid Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: NCI
Protocol IDs: CLB-9720, NCT00003190, CALGB-9720

24.

Phase III Randomized Study of Autologous Graft Versus Host Disease in Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: NCI
Protocol IDs: JHOC-97080106, JHOC-9726, NCI-V98-1453, NCT00003414

25.

Phase III Randomized Study of Interleukin-2 Plus Histamine Dihydrochloride (Maxamine) Versus No Further Therapy (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete Remission Following Consolidation Therapy

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MAXIM-MP-MA-0201, CWRU-MAXI-1998, NCT00003991

Select All on Page

Help with Results

A Service of the National Cancer Institute